Published in Cancer on June 15, 2008
High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation. J Thorac Oncol (2012) 1.28
Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed. J Thorac Oncol (2013) 1.04
EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor--a novel antibody for immunohistochemistry or AQUA technology. Clin Cancer Res (2011) 0.98
Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer. J Thorac Oncol (2010) 0.93
Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models. Breast Cancer Res (2010) 0.83
Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signatures. Transl Lung Cancer Res (2013) 0.83
Thymidylate synthase protein expression by IHC and gene copy number by SISH correlate and show great variability in non-small cell lung cancer. J Thorac Oncol (2012) 0.83
Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer? Transl Lung Cancer Res (2013) 0.82
Prognostic significance of the mRNA expression of ERCC1, RRM1, TUBB3 and TYMS genes in patients with non-small cell lung cancer. Exp Ther Med (2015) 0.81
Prognostic significance of thymidylate synthase in postoperative non-small cell lung cancer patients. Onco Targets Ther (2014) 0.80
Parameters for individualizing systemic therapy in non-small cell lung cancer. Drug Resist Updat (2010) 0.78
Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS). BMC Cancer (2012) 0.78
Expression of thymidylate synthase and orotate phosphoribosyltransferase in thymic carcinoma. Exp Ther Med (2012) 0.78
How close are we to customizing chemotherapy in early non-small cell lung cancer? Ther Adv Med Oncol (2011) 0.77
Topoisomerase I expression is associated with prognosis in postoperative non-small cell lung cancer patients. Thorac Cancer (2016) 0.77
Thymidylate Synthase as a Predictive Biomarker for Pemetrexed Response in NSCLC. Lung Cancer Int (2013) 0.77
Impact of thymidylate synthase protein expression on efficacy of chemotherapy in advanced lung cancer patients. Mol Clin Oncol (2013) 0.76
Tailoring treatment of nonsmall cell lung cancer by tissue type: role of pemetrexed. Pharmgenomics Pers Med (2009) 0.75
A method for biomarker directed survival prediction in advanced non-small-cell lung cancer patients treated with Carboplatin-based therapy. J Pers Med (2013) 0.75
Thymidylate synthase 1 (TS1) in-situ protein expression predicts the survival of Ewing/PNET. Fetal Pediatr Pathol (2010) 0.75
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med (1990) 11.57
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med (2006) 10.48
DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med (2007) 8.28
Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med (2002) 8.04
A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med (2004) 6.36
Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature (1957) 6.34
Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics (2002) 4.56
Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res (1995) 3.04
ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol (2001) 2.87
Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer (2006) 2.27
Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol (1997) 2.19
RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene (2003) 1.95
ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest (2005) 1.93
RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol (2004) 1.81
Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Res (2006) 1.68
What brown cannot do for you. Nat Biotechnol (2006) 1.51
Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells. Cancer Res (1995) 1.12
Practical p-value adjustment for optimally selected cutpoints. Stat Med (1996) 1.04
Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival. Clin Cancer Res (2000) 1.03
Increased levels of thymidylate synthetase in cells exposed to 5-fluorouracil. Mol Pharmacol (1984) 1.01
DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med (2007) 8.28
Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res (2005) 5.04
Non-small cell lung cancer. J Natl Compr Canc Netw (2010) 3.93
Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes (2012) 3.11
Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. Arch Intern Med (2008) 3.07
Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol (2005) 2.88
Racial diversity of actionable mutations in non-small cell lung cancer. J Thorac Oncol (2015) 2.80
Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst (2002) 2.77
Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest (2004) 2.73
Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res (2006) 2.68
Acidity generated by the tumor microenvironment drives local invasion. Cancer Res (2013) 2.63
Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res (2004) 2.54
Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol (2002) 2.51
Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res (2004) 2.33
Physician referral for fertility preservation in oncology patients: a national study of practice behaviors. J Clin Oncol (2009) 2.31
Incorporating genetic susceptibility feedback into a smoking cessation program for African-American smokers with low income. Cancer Epidemiol Biomarkers Prev (2002) 2.26
Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res (2005) 2.19
Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer. J Clin Oncol (2008) 2.18
Multi-platform, multi-site, microarray-based human tumor classification. Am J Pathol (2004) 2.14
Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol (2009) 2.13
Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res (2006) 2.12
Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem (2008) 2.07
Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol (2008) 1.97
RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene (2003) 1.95
ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest (2005) 1.93
Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol (2007) 1.91
Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene (2003) 1.88
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol (2010) 1.88
Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res (2005) 1.84
12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep (2012) 1.81
RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol (2004) 1.81
Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw (2006) 1.68
Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Res (2006) 1.68
Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther (2008) 1.65
Suicide in patients with pancreatic cancer. Cancer (2010) 1.62
Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol (2008) 1.61
Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia. Clin Cancer Res (2006) 1.61
Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol (2013) 1.55
Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood (2007) 1.54
Relationship between tumor size and survival among patients with resection of multiple synchronous lung cancers. J Thorac Oncol (2010) 1.50
Oligosaccharide analysis in urine by maldi-tof mass spectrometry for the diagnosis of lysosomal storage diseases. Clin Chem (2013) 1.48
Neuronal IP3 3-kinase is an F-actin-bundling protein: role in dendritic targeting and regulation of spine morphology. Mol Biol Cell (2009) 1.48
Malignant pleural mesothelioma: a comprehensive review. Cancer Control (2006) 1.47
Epstein-Barr and other herpesvirus infections in patients with early onset type 1 diabetes treated with daclizumab and mycophenolate mofetil. Clin Infect Dis (2012) 1.47
Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res (2003) 1.47
Proteomic contributions to personalized cancer care. Mol Cell Proteomics (2008) 1.46
The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood (2005) 1.43
Structure of a human inositol 1,4,5-trisphosphate 3-kinase: substrate binding reveals why it is not a phosphoinositide 3-kinase. Mol Cell (2004) 1.39
Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform. Int J Radiat Oncol Biol Phys (2009) 1.38
Agonist-induced regulation of mitochondrial and endoplasmic reticulum motility. Biochem J (2005) 1.37
Multiscale modelling of vascular tumour growth in 3D: the roles of domain size and boundary conditions. PLoS One (2011) 1.36
Mobilized peripheral blood SSCloALDHbr cells have the phenotypic and functional properties of primitive haematopoietic cells and their number correlates with engraftment following autologous transplantation. Br J Haematol (2003) 1.31
The guinea pig syndrome: improving clinical trial participation among thoracic patients. J Thorac Oncol (2007) 1.31
Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore. J Biol Chem (2001) 1.29
Lung cancer. Practice organization. Chest (2003) 1.27
ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood (2006) 1.27
Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol (2008) 1.26
Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res (2009) 1.25
A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. J Thorac Oncol (2007) 1.25
A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Int J Radiat Oncol Biol Phys (2009) 1.24
Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. J Clin Oncol (2004) 1.23
A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. Crit Rev Oncol Hematol (2004) 1.23
The feasibility of online genetic testing for lung cancer susceptibility: uptake of a web-based protocol and decision outcomes. Genet Med (2008) 1.23
Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer. J Thorac Oncol (2011) 1.23
Responses to online GSTM1 genetic test results among smokers related to patients with lung cancer: a pilot study. Cancer Epidemiol Biomarkers Prev (2009) 1.22
Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer. Am J Pathol (2009) 1.20
Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma. Arch Otolaryngol Head Neck Surg (2009) 1.19
Charting the landscape of tandem BRCT domain-mediated protein interactions. Sci Signal (2012) 1.19
Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol (2007) 1.19
Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women. Am J Clin Nutr (2002) 1.19
Determinants of metabotropic glutamate receptor-5-mediated Ca2+ and inositol 1,4,5-trisphosphate oscillation frequency. Receptor density versus agonist concentration. J Biol Chem (2002) 1.18
Persistent smoking after a diagnosis of lung cancer is associated with higher reported pain levels. J Pain (2009) 1.18
Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. J Clin Oncol (2008) 1.17
Two motifs target Batten disease protein CLN3 to lysosomes in transfected nonneuronal and neuronal cells. Mol Biol Cell (2003) 1.16
Regular aspirin use and lung cancer risk. BMC Cancer (2002) 1.15
Significance of sentinel lymph node micrometastases in human breast cancer. J Am Coll Surg (2007) 1.15
Prognostic factors for survival after salvage reirradiation of head and neck cancer. J Clin Oncol (2009) 1.14
The false discovery rate: a key concept in large-scale genetic studies. Cancer Control (2010) 1.14
Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. Lung Cancer (2005) 1.12
Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells. PLoS One (2012) 1.12
Continuous toxicity monitoring in phase II trials in oncology. Biometrics (2005) 1.12
Optimism bias leads to inconclusive results-an empirical study. J Clin Epidemiol (2010) 1.12
Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway. Cancer Res (2003) 1.12